Clinical Trial: "HB-adMSCs for the Treatment of Patients With Multiple Sclerosis"

U.S., Jan. 31 -- ClinicalTrials.gov registry received information related to the study (NCT06800404) titled '"HB-adMSCs for the Treatment of Patients With Multiple Sclerosis"' on Jan. 17.

Brief Summary: This protocol is part of a clinical study to evaluate efficacy and safety of multiple intravenous administrations of HB-adMSCs for the treatment of Multiple Sclerosis.

Study Start Date: June, 2025

Study Type: INTERVENTIONAL

Condition: Relapsing Remitting Multiple Sclerosis (RRMS) Multiple Sclerosis

Intervention: DRUG: Autologous HB-adMSCs

Autologous HB-adMSCs

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Hope Biosciences

Published by HT Digital Content Services with permission from Health Daily Digest....